# Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

> **NCT02926768** · PHASE1 · COMPLETED · sponsor: **Checkpoint Therapeutics, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Lung Diseases
- Adenocarcinoma

## Interventions

- **DRUG:** CK-101

## Key facts

- **NCT ID:** NCT02926768
- **Lead sponsor:** Checkpoint Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2020-09
- **Final completion:** 2022-06
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926768, "Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02926768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*